Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.60 |
| ▸ | CA9 | Q16790 | 12/20 | 0.60 |
| ▸ | CA12 | O43570 | 8/20 | 0.60 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.58 |
| ▸ | CA1 | P00915 | 8/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483895 | 0.85 | LMNA (0.45) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL3406988 | 0.84 | CA2 (0.62) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL11298641 | 0.81 | SENP3 (0.52) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL11296127 | 0.81 | TDP1 (0.44) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL1772255 | 0.81 | CYP3A4 (0.42) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL6313736 | 0.81 | CA2 (0.40) | CA2CA9CA12GLO1CA1 | |
| Hydrochloric Acid SCHEMBL11296130 | 0.80 | SENP3 (0.51) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL183418 | 0.80 | CA2 (0.39) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL17577475 | 0.79 | MAPK1 (0.42) | CA2CA9CA12GLO1CA1 | |
| SCHEMBL13452326 | 0.79 | CA2 (0.66) | CA2CA9CA12GLO1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153993-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-06-12 | — | — | CN | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2008006563-A1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| US-4453971-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-06-12 | — | — | US | disclosed |
| EP-0001515-B1 | HERBICIDAL SULFONAMIDES, AND PREPARATION AND USE THEREOF | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-05-18 | — | — | EP | disclosed |
| US-4369058-A | PLANT GROWTH REGULATORS, HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-18 | — | — | US | disclosed |
| US-4225337-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
| EP-0001515-A2 | Herbicidal sulfonamides, and preparation and use thereof | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | CA2 2138/4885CA9 869/4885CA12 1400/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | CA2 2138/4885CA9 869/4885CA12 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.